COR STOCK ANALYSIS

Cencora Inc. — price, returns and risk statistics

CORCencora Inc.

🇺🇸 USA · US · Healthcare · Medical Distribution

Value itDuel

Price summary

Last Close

296.51 $

Jul 2, 26

Market Cap

57.9 B $

Q1 2026 (TTM)

52-Week Range

252.16 $373.25 $

Return and risk cards

Total Return

%+2.6

Trailing 1-year performance

Volatility

%30.5

Price fluctuation measure

Sharpe Ratio

-1.07

Risk/Return ratio

Sortino Ratio

-0.90

Downside risk/return

Distance to Peak

%-20.6

Difference from 52-week peak

Maximum Drawdown

-%32.4

Deepest 1-year decline

Seasonality

Seasonality Chart

Year 2023
Year 2024
Year 2025
Current Period 2026
3/3 positive months

Periodic Returns

1M

+12.0%

3M

-8.5%

6M

-11.9%

YTD

-11.9%

1Y

+2.6%

3Y

+59.4%

Returns are computed from split-adjusted closes; dividends are not included.

YTD Return — Stock vs Asset Classes

Year-to-date
COR-11.9%Gold-3.2%Silver-10.4%S&P 500+9.3%

Stock and gold/silver returns are in USD (metals converted into the stock's currency). The S&P 500 index is measured in its own currency.

Monthly positivity

Monthly Avg Positive/Negative Close

Positive Count
Negative Count
Average Positive %
Average Negative %

Frequently Asked Questions

What is the current Cencora Inc. (COR) stock price?

COR last closed at 296.51 $ (Jul 2, 26). Price data is refreshed after every trading day.

What is the P/E ratio of COR?

Cencora Inc. trades at a trailing-twelve-month P/E of 22.73. See the comparison tables on the Peers tab for the industry context.

What is the market capitalization of Cencora Inc.?

Cencora Inc. (COR) has a market capitalization of approximately 57.9 B $ as of the latest reported period.

Who are the main competitors of COR?

Key peers of Cencora Inc. include Sigma Healthcare Ltd, Selçuk Ecza Deposu Ticaret ve Sanayi A.S., Ebos Group Ltd. A detailed metric comparison is available on the Peers tab.

Go deeper on COR

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.